Pancreatic Ductal Adenocarcinoma Clinical Trials in Fairfax, Virginia

25 recruitingFairfax, Virginia

Showing 120 of 25 trials

Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.448 enrolled12 locationsNCT06835569
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Colorectal, CancerHormone Receptor-Positive Breast CarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd174 enrolled3 locationsNCT07454642
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Colorectal, CancerNon-small Cell Lung CancerSolid Tumor+1 more
Astellas Pharma Inc364 enrolled20 locationsNCT07094204
Recruiting
Phase 1Phase 2

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phanes Therapeutics40 enrolled6 locationsNCT05431270
Recruiting
Phase 1Phase 2

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled21 locationsNCT05379985
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1Phase 2

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Colorectal, CancerMelanomaHead and Neck Squamous Cell Carcinoma+2 more
Ipsen220 enrolled12 locationsNCT06305247
Recruiting
Phase 1Phase 2

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Colorectal, CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma+2 more
Verastem, Inc.295 enrolled14 locationsNCT07020221
Recruiting

Pancreatic Cancer Early Detection Consortium

Pancreatic Ductal AdenocarcinomaPancreas CancerGenetic Predisposition+1 more
Arbor Research Collaborative for Health20,000 enrolled60 locationsNCT04970056
Recruiting
Phase 1Phase 2

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal, CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.534 enrolled53 locationsNCT06128551
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal, CancerPancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma+3 more
Revolution Medicines, Inc.1,130 enrolled32 locationsNCT06445062
Recruiting
Phase 1Phase 2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 1

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Colorectal, CancerEsophageal CancerGastric Cancer+6 more
Sutro Biopharma, Inc.200 enrolled6 locationsNCT07227168
Recruiting
Phase 1

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Triple-Negative Breast CancerGastric CancerGastroesophageal-junction Cancer+9 more
Dren Bio96 enrolled10 locationsNCT06999187
Recruiting
Phase 1Phase 2

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893